培哚普利联合瑞舒伐他汀钙治疗冠心病行经皮冠状动脉介入术患者的效果

Effects of Perindopril combined with Rosuvastatin calcium in treatment of patients with coronary heart disease undergoing percutaneous coronary intervention

目的:观察培哚普利联合瑞舒伐他汀钙治疗冠状动脉粥样硬化性心脏病(冠心病)行经皮冠状动脉介入术(PCI)患者的效果。方法:选取2020年2月至2021年6月该院收治的89例冠心病患者进行前瞻性研究,根据门诊序号单双数将其分为对照组45例和观察组44例。两组均行PCI,对照组采用瑞舒伐他汀钙治疗,观察组在对照组基础上联合培哚普利治疗。比较两组治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、心排血量(CO)]水平、血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)]水平、术后6个月缺血事件发生率,以及不良反应发生率。结果:治疗后,两组LVEF、CO、NO水平均高于治疗前,且观察组高于对照组,两组LVEDD、ET-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组缺血事件发生率和不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:培哚普利联合瑞舒伐他汀钙治疗行PCI冠心病患者可改善心功能指标水平和血管内皮功能指标水平,效果优于单纯瑞舒伐他汀钙治疗。

Objective:To observe effects of Perindopril combined with Rosuvastatin calcium in treatment of patients with coronary heart disease undergoing percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 89 patients with coronary heart disease admitted to this hospital from February 2020 to June 2021.According to the even and odd numbers of the outpatient numbers,they were divided into control group(odd number,45 cases)and observation group(even number,44 cases).PCI was performed in both groups.The control group was treated with Rosuvastatin calcium,while the observation group was treated with Perindopril on the basis of that of the control group.The levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),cardiac output(CO)]and the vascular endothelial function indexes[endothelin-1(ET-1),nitric oxide(NO)]before and after the treatment,the incidence of ischemic events,and the incidence of adverse reactions at 6-month follow up were compared between the two groups.Results:After the treatment,the LVEF,CO,and serum NO levels in both groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the LVEDD and serum ET-1 levels in both groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there were no statistically significant differences in the incidence of ischemic events and adverse reactions between the two groups(P>0.05).Conclusions:Perindopril combined with Rosuvastatin calcium can improve the levels of cardiac function indexes and vascular endothelial function indexes in the patients with coronary heart disease undergoing PCI.Moreover,it is superior to single Rosuvastatin calcium treatment.